Xtant Medical Holdings, Inc.

NYSEAM:XTNT Stock Report

Market Cap: US$58.9m

Xtant Medical Holdings Future Growth

Future criteria checks 3/6

Xtant Medical Holdings is forecast to grow earnings and revenue by 52.6% and 4.6% per annum respectively while EPS is expected to grow by 52.6% per annum.

Key information

52.6%

Earnings growth rate

52.60%

EPS growth rate

Medical Equipment earnings growth16.4%
Revenue growth rate4.6%
Future return on equityn/a
Analyst coverage

Low

Last updated13 May 2026

Recent future growth updates

Recent updates

Narrative Update • Jun 26

XTNT: Licensing Deal And Product Recall Resolution Will Drive Future Upside

Analysts have updated their price target for Xtant Medical Holdings to $1.23 from $1.50, citing refreshed assumptions around revenue growth, profit margins, discount rates, a revised forward P/E, and recent Street research that resumed coverage with a positive stance on the stock. What’s in the News for Xtant Medical Holdings Xtant Medical Holdings increased its full-year 2026 revenue guidance to a range of US$101 million to US$105 million, from US$95 million to US$99 million, reflecting the exclusive license agreement with Dilon Technologies and the expected contribution from HEMOBLAST Bellows.
New Narrative • Jun 01

Expanded Biologics Portfolio And New Hemostatic Agent Will Support Long Term Commercial Upside

Catalysts About Xtant Medical Holdings Xtant Medical Holdings develops and markets biologic and regenerative solutions for spine, orthopedic surgery, and surgical repair and wound care. What are the underlying business or industry changes driving this perspective?
New Narrative • May 15

Sales Integration And Margin Pressures Will Shape Biologics Focused Future

Catalysts About Xtant Medical Holdings Xtant Medical Holdings develops and supplies biologic and related products for spine surgery, orthopedic procedures and surgical repair and wound care. What are the underlying business or industry changes driving this perspective?
Analysis Article • Mar 02

Shareholders Are Thrilled That The Xtant Medical Holdings (NYSEMKT:XTNT) Share Price Increased 186%

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right...

Earnings and Revenue Growth Forecasts

NYSEAM:XTNT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20281237463
12/31/20271120233
12/31/2026102-7-4-43
3/31/2026122289N/A
12/31/202513451013N/A
9/30/2025133258N/A
6/30/2025128-5-32N/A
3/31/2025122-12-9-5N/A
12/31/2024117-16-16-12N/A
9/30/2024114-18-17-13N/A
6/30/2024111-3-18-16N/A
3/31/2024101-2-15-13N/A
12/31/2023911-11-10N/A
9/30/2023783-12-11N/A
6/30/202368-9-11-9N/A
3/31/202363-8-8-7N/A
12/31/202258-8-7-5N/A
9/30/202257-9-5-3N/A
6/30/202256-8-3-1N/A
3/31/202256-7-11N/A
12/31/202155-5-20N/A
9/30/202155-3-11N/A
6/30/202156-302N/A
3/31/202151-5-20N/A
12/31/202053-7-2-1N/A
9/30/202056-8-3-2N/A
6/30/202058-8-4-3N/A
3/31/202063-8-4-3N/A
12/31/201965-8N/A0N/A
9/30/201966-63N/A2N/A
6/30/201968-65N/A2N/A
3/31/201971-68N/A1N/A
12/31/201872-70N/A1N/A
9/30/201873-42N/A0N/A
6/30/201876-47N/A1N/A
3/31/201878-52N/A-1N/A
12/31/201783-52N/A-1N/A
9/30/201788-29N/A-4N/A
6/30/201791-25N/A-7N/A
3/31/201791-20N/A-15N/A
12/31/201690-19N/A-14N/A
9/30/201688-3N/A-11N/A
6/30/201682-5N/A-13N/A
3/31/201671-4N/A-6N/A
12/31/201559-2N/A-9N/A
9/30/201546-17N/A-11N/A
6/30/201537-12N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XTNT's forecast earnings growth (52.6% per year) is above the savings rate (3.5%).

Earnings vs Market: XTNT's earnings (52.6% per year) are forecast to grow faster than the US market (18.6% per year).

High Growth Earnings: XTNT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: XTNT's revenue (4.6% per year) is forecast to grow slower than the US market (12.7% per year).

High Growth Revenue: XTNT's revenue (4.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if XTNT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/28 11:41
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xtant Medical Holdings, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael GormanBTIG
null nullCG Capital
Chase KnickerbockerCraig-Hallum Capital Group LLC